Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells
Fetal growth restriction (FGR) is a major complication of prenatal ischemic/hypoxic exposure and affects 5%–10% of pregnancies. It causes various disorders, including neurodevelopmental disabilities due to chronic hypoxia, circulatory failure, and malnutrition via the placenta, and there is no estab...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Cellular Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fncel.2020.00212/full |
id |
doaj-0819522d34f34b02b8c0f8d0568b9e60 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuma Kitase Yuma Kitase Yoshiaki Sato Sakiko Arai Sakiko Arai Atsuto Onoda Atsuto Onoda Kazuto Ueda Shoji Go Haruka Mimatsu Haruka Mimatsu Mahboba Jabary Mahboba Jabary Toshihiko Suzuki Miharu Ito Akiko Saito Akihiro Hirakawa Takeo Mukai Tokiko Nagamura-Inoue Yoshiyuki Takahashi Masahiro Tsuji Masahiro Hayakawa |
spellingShingle |
Yuma Kitase Yuma Kitase Yoshiaki Sato Sakiko Arai Sakiko Arai Atsuto Onoda Atsuto Onoda Kazuto Ueda Shoji Go Haruka Mimatsu Haruka Mimatsu Mahboba Jabary Mahboba Jabary Toshihiko Suzuki Miharu Ito Akiko Saito Akihiro Hirakawa Takeo Mukai Tokiko Nagamura-Inoue Yoshiyuki Takahashi Masahiro Tsuji Masahiro Hayakawa Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells Frontiers in Cellular Neuroscience umbilical cord-derived mesenchymal stromal cells fetal growth restriction mesenchymal stem cell neurodevelopment stem cells |
author_facet |
Yuma Kitase Yuma Kitase Yoshiaki Sato Sakiko Arai Sakiko Arai Atsuto Onoda Atsuto Onoda Kazuto Ueda Shoji Go Haruka Mimatsu Haruka Mimatsu Mahboba Jabary Mahboba Jabary Toshihiko Suzuki Miharu Ito Akiko Saito Akihiro Hirakawa Takeo Mukai Tokiko Nagamura-Inoue Yoshiyuki Takahashi Masahiro Tsuji Masahiro Hayakawa |
author_sort |
Yuma Kitase |
title |
Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells |
title_short |
Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells |
title_full |
Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells |
title_fullStr |
Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells |
title_full_unstemmed |
Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells |
title_sort |
establishment of a novel fetal growth restriction model and development of a stem-cell therapy using umbilical cord-derived mesenchymal stromal cells |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cellular Neuroscience |
issn |
1662-5102 |
publishDate |
2020-07-01 |
description |
Fetal growth restriction (FGR) is a major complication of prenatal ischemic/hypoxic exposure and affects 5%–10% of pregnancies. It causes various disorders, including neurodevelopmental disabilities due to chronic hypoxia, circulatory failure, and malnutrition via the placenta, and there is no established treatment. Therefore, the development of treatments is an urgent task. We aimed to develop a new FGR rat model with a gradual restrictive load of uterus/placental blood flow and to evaluate the treatment effect of the administration of umbilical cord-derived mesenchymal stromal cells (UC-MSCs). To create the FGR rat model, we used ameroid constrictors that had titanium on the outer wall and were composed of C-shaped casein with a notch and center hole inside that gradually narrowed upon absorbing water. The ameroid constrictors were attached to bilateral ovarian/uterine arteries on the 17th day of pregnancy to induce chronic mild ischemia, which led to FGR with over 20% bodyweight reduction. After the intravenous administration of 1 × 105 UC-MSCs, we confirmed a significant improvement in the UC-MSC group in a negative geotaxis test at 1 week after birth and a rotarod treadmill test at 5 months old. In the immunobiological evaluation, the total number of neurons counted via the stereological counting method was significantly higher in the UC-MSC group than in the vehicle-treated group. These results indicate that the UC-MSCs exerted a treatment effect for neurological impairment in the FGR rats. |
topic |
umbilical cord-derived mesenchymal stromal cells fetal growth restriction mesenchymal stem cell neurodevelopment stem cells |
url |
https://www.frontiersin.org/article/10.3389/fncel.2020.00212/full |
work_keys_str_mv |
AT yumakitase establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT yumakitase establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT yoshiakisato establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT sakikoarai establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT sakikoarai establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT atsutoonoda establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT atsutoonoda establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT kazutoueda establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT shojigo establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT harukamimatsu establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT harukamimatsu establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT mahbobajabary establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT mahbobajabary establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT toshihikosuzuki establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT miharuito establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT akikosaito establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT akihirohirakawa establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT takeomukai establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT tokikonagamurainoue establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT yoshiyukitakahashi establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT masahirotsuji establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells AT masahirohayakawa establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells |
_version_ |
1724583198526013440 |
spelling |
doaj-0819522d34f34b02b8c0f8d0568b9e602020-11-25T03:28:35ZengFrontiers Media S.A.Frontiers in Cellular Neuroscience1662-51022020-07-011410.3389/fncel.2020.00212524508Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal CellsYuma Kitase0Yuma Kitase1Yoshiaki Sato2Sakiko Arai3Sakiko Arai4Atsuto Onoda5Atsuto Onoda6Kazuto Ueda7Shoji Go8Haruka Mimatsu9Haruka Mimatsu10Mahboba Jabary11Mahboba Jabary12Toshihiko Suzuki13Miharu Ito14Akiko Saito15Akihiro Hirakawa16Takeo Mukai17Tokiko Nagamura-Inoue18Yoshiyuki Takahashi19Masahiro Tsuji20Masahiro Hayakawa21Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanFaculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Yamaguchi, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanClinical Research Center, Division of Biostatistics and Data Science, Medical and Dental University, Tokyo, JapanDepartment of Cell Processing and Transfusion, Institute of Medical Science, University of Tokyo, Tokyo, JapanDepartment of Cell Processing and Transfusion, Institute of Medical Science, University of Tokyo, Tokyo, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDepartment of Food and Nutrition, Faculty of Home Economics, Kyoto Women’s University, Kyoto, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanFetal growth restriction (FGR) is a major complication of prenatal ischemic/hypoxic exposure and affects 5%–10% of pregnancies. It causes various disorders, including neurodevelopmental disabilities due to chronic hypoxia, circulatory failure, and malnutrition via the placenta, and there is no established treatment. Therefore, the development of treatments is an urgent task. We aimed to develop a new FGR rat model with a gradual restrictive load of uterus/placental blood flow and to evaluate the treatment effect of the administration of umbilical cord-derived mesenchymal stromal cells (UC-MSCs). To create the FGR rat model, we used ameroid constrictors that had titanium on the outer wall and were composed of C-shaped casein with a notch and center hole inside that gradually narrowed upon absorbing water. The ameroid constrictors were attached to bilateral ovarian/uterine arteries on the 17th day of pregnancy to induce chronic mild ischemia, which led to FGR with over 20% bodyweight reduction. After the intravenous administration of 1 × 105 UC-MSCs, we confirmed a significant improvement in the UC-MSC group in a negative geotaxis test at 1 week after birth and a rotarod treadmill test at 5 months old. In the immunobiological evaluation, the total number of neurons counted via the stereological counting method was significantly higher in the UC-MSC group than in the vehicle-treated group. These results indicate that the UC-MSCs exerted a treatment effect for neurological impairment in the FGR rats.https://www.frontiersin.org/article/10.3389/fncel.2020.00212/fullumbilical cord-derived mesenchymal stromal cellsfetal growth restrictionmesenchymal stem cellneurodevelopmentstem cells |